Addendum

Teprotumumab (thyroid eye disease) – Addendum to Project A26-18

Report documents

Indication:

Adults with moderate to severe thyroid eye disease

Result of dossier assessment:

Patients in the acute disease phase receiving first-line treatment: unchanged after addendum: added benefit not proven
Patients in the acute disease phase who are eligible for second-line treatment: unchanged after addendum: added benefit not proven
Patients in the chronic disease phase: unchanged after addendum: added benefit not proven

20-08-2026 A G-BA decision was published.
G-BA documents on this decision

Project no.: A26-80
Commission: Commission awarded on 07.07.2026 by the Federal Joint Committee (GBA).
Report type: Addendum
Status: Commission completed
Department/Division: Drug Assessment
Topic: Immune system and infections
Note: If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
DOI: https://doi.org/10.60584/A26-80

Press contact

+49 221 356850

press@iqwig.de

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.